Swapnil S Potdar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3726100/publications.pdf Version: 2024-02-01



SWADNIL S DOTDAD

#	Article	IF	CITATIONS
1	Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence, 2019, 1, 568-577.	16.0	99
2	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
3	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604.	4.1	68
4	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naÃ ⁻ ve glioblastoma. BMC Cancer, 2019, 19, 628.	2.6	55
5	ALDH1A1â€related stemness in highâ€grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTORâ€PI3K/aurora kinase inhibitors. Journal of Pathology, 2020, 250, 159-169.	4.5	37
6	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia, 2020, 35, 1964-1975.	7.2	35
7	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. British Journal of Cancer, 2019, 120, 435-443.	6.4	24
8	Feasibility study of using highâ€ŧhroughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clinical and Translational Medicine, 2019, 8, 33.	4.0	20
9	Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. Cancers, 2020, 12, 92.	3.7	20
10	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget, 2017, 8, 22606-22615.	1.8	13
11	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	5.4	12
12	Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i> -Mutant Lung Cancers. Molecular Cancer Therapeutics, 2019, 18, 1863-1874.	4.1	8
13	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	3.3	7
14	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	7.2	6
15	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Reports Medicine, 2021, 2, 100373.	6.5	6
16	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. Synergy, 2014, 1, 78.	1.1	4
17	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701.	2.7	4
18	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. Cancers, 2021, 13, 2907.	3.7	3

#	Article	IF	CITATIONS
19	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	1.4	1
20	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	1.4	1
21	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	1.4	0
22	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. Blood, 2018, 132, 3975-3975.	1.4	0